Brilliant Violet 785™ anti-human CD13

Catalog # / Size: 2108630 / 100 tests

2108625 / 25 tests

Clone: WM15

Isotype: Mouse IgG1, κ

Reactivity: Human, Mouse, Non-human

primate,Other,Rat

Preparation: The antibody was purified by affinity

chromatography and conjugated with Brilliant Violet 785™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 785™ and

unconjugated antibody.


Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and BSA

(origin USA).

Workshop Number: IV M44

Concentration: Lot-specific



Human peripheral blood granulocytes were stained with CD13 (clone WM15) Brilliant Violet 785™ (filled histogram) or Mouse IgG1, κ Brilliant Violet 785™ isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells or 5 μ l per 100 μ l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes:

Additional reported applications (for the relevant formats) include: inhibition of tumor-cell invasion and blocking of aminopeptidase activities^{2,3}, and immunohistochemical staining of acetone-fixed frozen tissue sections⁵. WM15 does not recognize formalin-fixed or paraffin-embedded tissue sections⁵.

Application

1. Shipp M, et al. 1993. Blood 82:1052.

References: 2. Larsen S, et a

2. Larsen S, et al. 1996. J. Exp. Med. 184:183.

Description: CD13 is a 150-170 kD type II transmembrane glycoprotein also known as

aminopeptidase N, APN, and gp150. This zinc metallopeptidase is expressed as a homodimer on granulocytes, myeloid progenitors, endothelial cells, epithelial cells

and subset of granular lymphoid cells. It is not expressed on platelets or erythrocytes. CD13 is thought to be involved in the metabolism of many regulatory peptides and functions in antigen processing and the cleavage of chemokines such as MIP-1. CD13 serves as the cellular receptor for Coronavirus.

Antigen

1. Shipp M, et al. 1993. Blood 82:1052.

References: 2. Larsen S, et al. 1996. J. Exp. Med. 184:183.